Organic Chemistry: An Indian Journal ISSN (PRINT): 0974-7516
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Antianginal Agents New Findings
Effective treatment of coronary artery disease requires a whole lot of wonderful goals: controlling symptomatic angina, lowering the damaging events associated with ischemia, and providing vascular safety towards the atherosclerotic process. While there are more than a few of remedy alternatives for controlling symptomatic angina, which include medical therapy using beta blockers, calcium channel blockers, and nitrates and coronary revascularization, there are a giant quantity of patients who may gain from a therapeutic mechanism of action special than those associated with conventional antianginal remedy. Ranolazine and ivabradine are newer, nontraditional antianginal remedy used for the remedy of symptomatic angina within the placing of chronic, solid ischemic coronary heart disease. Ranolazine is approved in the U.S. And Europe for remedy both as first line therapy and as add-on therapy in addition to traditional medical therapy. Ivabradine is approved to be used in Europe but now not inside the U.S. At this time.